Murphy & Mullick Capital Management’s AstraZeneca AZN Stock Holding History

Murphy & Mullick Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$388K	Hold	2,047	–	–	0.24%	90
2026 Q1	$403K	Sell	2,047 -14	-0.7%	-$2.7K	0.3%	78
2025 Q4	$379K	Sell	2,061 -51	-2%	-$8.95K	0.27%	81
2025 Q3	$327K	Hold	2,112	–	–	0.24%	90
2025 Q2	$307K	Buy	2,112 +125	+6%	+$17.5K	0.25%	86
2025 Q1	$292K	Sell	1,987 -43	-2%	-$6.22K	0.28%	85
2024 Q4	$266K	Buy	+2,030	New	+$284K	0.25%	93

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Murphy & Mullick Capital Management's AZN Position: Q2 2026 in Review

Murphy & Mullick Capital Management held its AstraZeneca (AZN) position steady in Q2 2026 at 2,047 shares worth $388K. The position accounts for 0.24% of the portfolio, ranked #90.

Murphy & Mullick Capital Management first reported a position in AZN in Q4 2024 and has held it in 7 quarters since. The position peaked at $403K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Murphy & Mullick Capital Management held 2,047 shares of AstraZeneca worth $388K as of Q2 2026.
Murphy & Mullick Capital Management left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.24% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #90 holding.
Murphy & Mullick Capital Management first reported a position in AstraZeneca in Q4 2024 and has held it in 7 quarters since.
Murphy & Mullick Capital Management's AstraZeneca position peaked at $403K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.